79 related articles for article (PubMed ID: 7743524)
1. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
Silvani A; Ferrari G; Paonessa G; Toniatti C; Parmiani G; Colombo MP
Cancer Res; 1995 May; 55(10):2200-5. PubMed ID: 7743524
[TBL] [Abstract][Full Text] [Related]
2. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
Lu C; Rak JW; Kobayashi H; Kerbel RS
Cancer Res; 1993 Jun; 53(12):2708-11. PubMed ID: 8504408
[TBL] [Abstract][Full Text] [Related]
3. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
4. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
[TBL] [Abstract][Full Text] [Related]
6. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells.
Oh JW; Katz A; Harroch S; Eisenbach L; Revel M; Chebath J
Oncogene; 1997 Jul; 15(5):569-77. PubMed ID: 9247310
[TBL] [Abstract][Full Text] [Related]
7. Selection and characterization of a variant of human melanoma cell line, A375 resistant to growth inhibitory effects of oncostatin M (OM): coresistant to interleukin 6 (IL-6).
McDonald VL; Dick KO; Malik N; Shoyab M
Growth Factors; 1993; 9(3):167-75. PubMed ID: 8274294
[TBL] [Abstract][Full Text] [Related]
8. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130).
Geisterfer M; Richards CD; Gauldie J
Cytokine; 1995 Aug; 7(6):503-9. PubMed ID: 8580365
[TBL] [Abstract][Full Text] [Related]
9. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
[TBL] [Abstract][Full Text] [Related]
10. Loss of oncostatin M receptor beta in metastatic melanoma cells.
Lacreusette A; Nguyen JM; Pandolfino MC; Khammari A; Dreno B; Jacques Y; Godard A; Blanchard F
Oncogene; 2007 Feb; 26(6):881-92. PubMed ID: 16909117
[TBL] [Abstract][Full Text] [Related]
11. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
12. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor.
Hooper WC; Phillips DJ; Evatt BL
Thromb Haemost; 1997 May; 77(5):1014-9. PubMed ID: 9184420
[TBL] [Abstract][Full Text] [Related]
13. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.
Borsellino N; Bonavida B; Ciliberto G; Toniatti C; Travali S; D'Alessandro N
Cancer; 1999 Jan; 85(1):134-44. PubMed ID: 9921985
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells.
Cichy J; Rose-John S; Potempa J; Pryjma J; Travis J
J Immunol; 1997 Dec; 159(11):5648-53. PubMed ID: 9548508
[TBL] [Abstract][Full Text] [Related]
15. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 enhances the growth of human melanoma cells derived form primary but not from metastatic tumours.
García-Vázquez MD; Boyano MD; Cañavate ML; Gardeazabal J; de Galdeano AG; López-Michelena T; Ratón JA; Izu R; Díaz-Ramón JL; Díaz-Pérez JL
Eur Cytokine Netw; 2000 Dec; 11(4):654-61. PubMed ID: 11125310
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
[TBL] [Abstract][Full Text] [Related]
19. Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression.
Durda PJ; Dunn IS; Rose LB; Butera D; Benson EM; Pandolfi F; Kurnick JT
Mol Cancer Res; 2003 Apr; 1(6):411-9. PubMed ID: 12692260
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors.
Sidell N; Taga T; Hirano T; Kishimoto T; Saxon A
J Immunol; 1991 Jun; 146(11):3809-14. PubMed ID: 2033252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
